drugset / Trial / NCT04103060
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo
Timeline
- Start
- 2019-09-27
- Primary completion
- 2020-11-03
- Completion
- 2020-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cerdulatinib | Small molecule | 0.37 % | Topical |